COMMODORE CAPITAL LP - Q2 2021 holdings

$287 Million is the total value of COMMODORE CAPITAL LP's 29 reported holdings in Q2 2021. The portfolio turnover from Q1 2021 to Q2 2021 was 25.8% .

 Value Shares↓ Weighting
ACRS BuyACLARIS THERAPEUTICS INC$29,307,000
+13.1%
1,668,987
+62.3%
10.21%
-1.1%
STSA BuySATSUMA PHARMACEUTICALS INC$21,832,000
+51.9%
3,096,729
+27.3%
7.61%
+32.9%
CELC NewCELCUITY INC$20,903,000870,967
+100.0%
7.28%
CCCC  C4 THERAPEUTICS INC$18,205,000
+2.3%
481,0940.0%6.34%
-10.5%
CBAY BuyCYMABAY THERAPEUTICS INC$15,388,000
+13.6%
3,529,465
+18.3%
5.36%
-0.6%
CNST BuyCONSTELLATION PHARMCETICLS I$14,901,000
+72.9%
440,869
+19.7%
5.19%
+51.2%
CYTK NewCYTOKINETICS INC$13,938,000704,317
+100.0%
4.86%
KURA BuyKURA ONCOLOGY INC$12,958,000
-12.1%
621,493
+19.2%
4.52%
-23.1%
COGT BuyCOGENT BIOSCIENCES INC$11,091,000
-0.5%
1,367,582
+7.8%
3.86%
-13.0%
ISEE BuyIVERIC BIO INC$11,031,000
+3.2%
1,748,241
+1.1%
3.84%
-9.7%
CLDX SellCELLDEX THERAPEUTICS INC NEW$10,816,000
+41.9%
323,437
-12.6%
3.77%
+24.1%
MGNX BuyMACROGENICS INC$10,579,000
+612.4%
393,850
+744.6%
3.69%
+522.6%
VTGN SellVISTAGEN THERAPEUTICS INC$10,494,000
+32.1%
3,331,315
-10.7%
3.66%
+15.5%
PTGX SellPROTAGONIST THERAPEUTICS INC$9,452,000
+4.4%
210,600
-39.8%
3.29%
-8.7%
EPIX BuyESSA PHARMA INC$8,054,000
+56.8%
281,911
+59.4%
2.81%
+37.1%
KRON  KRONOS BIO INC$7,157,000
-18.2%
298,8390.0%2.49%
-28.4%
GNCA BuyGENOCEA BIOSCIENCES INC$6,855,000
-11.9%
2,929,447
+2.0%
2.39%
-23.0%
MREO BuyMEREO BIOPHARMA GROUP PLCads$6,529,000
-5.4%
2,059,729
+0.5%
2.28%
-17.3%
DYN SellDYNE THERAPEUTICS INC$6,420,000
-3.9%
305,125
-29.1%
2.24%
-15.9%
XENE BuyXENON PHARMACEUTICALS INC$6,076,000
+12.6%
326,336
+8.3%
2.12%
-1.5%
MRSN  MERSANA THERAPEUTICS INC$5,829,000
-16.1%
429,2280.0%2.03%
-26.6%
KALV BuyKALVISTA PHARMACEUTICALS INC$5,431,000
-1.4%
226,671
+5.7%
1.89%
-13.8%
PMVP  PMV PHARMACEUTICALS INC$4,270,000
+3.9%
125,0000.0%1.49%
-9.2%
IVA  INVENTIVA SAads$3,581,000
-7.3%
262,6580.0%1.25%
-18.9%
MCRB BuySERES THERAPEUTICS INC$3,469,000
+19.3%
145,453
+2.9%
1.21%
+4.3%
NewCATABASIS PHARMACEUTICALS IN$3,412,0001,617,000
+100.0%
1.19%
VRDN BuyVIRIDIAN THERAPEUTICS INC$3,409,000
+9.8%
186,405
+0.3%
1.19%
-3.9%
SBTX  SILVERBACK THERAPEUTICS INC$3,001,000
-29.2%
97,1430.0%1.05%
-38.0%
BLSA  BCLS ACQUISITION CORP$2,633,000
-0.4%
250,0000.0%0.92%
-12.9%
LSAQ ExitLIFESCI ACQUISITION II CORP$0-100,000
-100.0%
-0.40%
SNDX ExitSYNDAX PHARMACEUTICALS INC$0-236,500
-100.0%
-2.11%
RLMD ExitRELMADA THERAPEUTICS INC$0-161,565
-100.0%
-2.27%
ExitTRILLIUM THERAPEUTICS INC$0-795,868
-100.0%
-3.40%
FPRX ExitFIVE PRIME THERAPEUTICS INC$0-361,344
-100.0%
-5.42%
Original filings

The following EDGAR filing(s) were analyzed to create this report:

  • View 13F-HR/A filed 2021-10-14
Signatures

The EDGAR filing(s) were signed by:

Top long-term holdings
NameQuarters ownedLatest quarter ownedMax weighting
XENON PHARMACEUTICALS INC12Q3 202310.3%
COGENT BIOSCIENCES INC12Q3 202310.4%
VIRIDIAN THERAPEUTICS INC11Q3 20238.9%
CYMABAY THERAPEUTICS INC11Q2 20235.4%
KURA ONCOLOGY INC11Q3 20237.1%
CELLDEX THERAPEUTICS INC NEW11Q3 20233.8%
ACLARIS THERAPEUTICS INC10Q1 202310.4%
CELCUITY INC10Q3 20237.3%
KALVISTA PHARMACEUTICALS INC10Q2 20232.2%
MERUS N V9Q3 202312.5%

View COMMODORE CAPITAL LP's complete holdings history.

Latest significant ownerships (13-D/G)
COMMODORE CAPITAL LP Q2 2021 significant holdings filed using form 13D/G when ownership exceeds 5% of a company's total stock issue.
FiledShares Percentage
Ambrx Biopharma Inc.April 27, 202331,181,9838.1%
BELLUS Health Inc.March 30, 20236,579,3595.2%
IMARA Inc.February 21, 20232,840,75410.8%
Karyopharm Therapeutics Inc.February 14, 20231,935,6091.7%
VistaGen Therapeutics, Inc.Sold outFebruary 14, 202300.0%
Satsuma Pharmaceuticals, Inc.Sold outNovember 16, 202200.0%
GENOCEA BIOSCIENCES, INC.February 14, 20223,079,7565.4%

View COMMODORE CAPITAL LP's complete significant-ownership history.

Latest filings
TypeFiled
SC 13G2024-03-21
13F-HR/A2024-02-14
13F-HR2024-02-14
SC 13G/A2024-02-14
SC 13G/A2024-02-14
SC 13G/A2024-02-14
SC 13G/A2024-02-14
SC 13G/A2024-02-14
SC 13G/A2024-02-14
SC 13G/A2024-02-14

View COMMODORE CAPITAL LP's complete filings history.

Compare quarters

Issues

The following issues were detected while analyzing the report:

  • The reported has been restated
  • The reported has been amended

Export COMMODORE CAPITAL LP's holdings